Industry Supported Symposia

Industry Supported Symposia

Friday, 13 May 2016
11:00–12:00 Independent Symposium (Springer Healthcare IME supported by Eli Lilly):
Evolution of the individualized treatment landscape for advanced NSCLC
Room:
Empress Grand Hall, 3rd floor
11:00 Welcome and introduction
Chairman: Tony Mok,Hong Kong
11:05 How best to manage patients with non-squamous NSCLC without EGFR/ALK mutations
Speaker: Ross Andrew Soo, Singapore
11:30 Therapeutic options for patients with advanced squamous NSCLC
Speaker: Giorgio Scagliotti, Italy
11:55 Closing remarks
Chairman: Tony Mok, Hong Kong
17.00-18.00 Symposium supported by Boehringer Ingelheim:
NSCLC treatment: The evolving therapeutic landscape
Room:
Empress Grand Hall, 3rd floor
17:00 Overview of treatment of NSCLC
Chairman: Sumitra Thongprasert, Thailand
17:05 First-line treatment of EGFR M+ NSCLC: an update on second generation tyrosine kinase inhibitors (TKIs)
Speaker: James Yang, Taiwan
17:30 Next-generation EGFR inhibitors: treatment options following resistance
Speaker: James Yang, Taiwan
17:40 Anti-angiogenic treatment in NSCLC: What we know, what we do
Speaker: Nick Pavlakis, Australia
17:55 Final questions, summary and meeting close
Chairman: Sumitra Thongprasert, Thailand

 

Saturday, 14 May 2016
07.00-07.45 Symposium Supported by AstraZeneca:
Identification and Management of EGFR-TKIs Resistance in Clinical Practice
Room:
Chiang Mai room 1-2, 2nd floor
07.00 Identification and Management of EGFR-TKIs Resistance in Clinical Practice
Chairman: Virote Sriuranpong, Thailand
Speaker: Pasi A.Jänne, USA
11.25-12.25 Symposium supported by Pfizer:
ALK Inhibitors in NSCLC: Today and Tomorrow
Room:
Empress Grand Hall, 3rd floor
11:25 Welcome and Introduction
Chairman: Sumitra Thongprasert, Thailand
11:30 Setting standard of care in ALK-positive NSCLC
Speaker: Prof Ken O’Byrne, Australia
12:00 Optimizing the continuum of care in ALK-positive NSCLC patients
Case presentation: Daniel Tan SW, Singapore
12:20 Summary and Closing
Chairman: Sumitra Thongprasert, Thailand
12.35-13.35 Symposium supported by Roche:
Optimizing Treatment Options in Oncogene-Driven NSCLC and Precision Medicine

Room: Empress Grand Hall, 3rd floor
12.35 Opening and welcome
Speaker: Virote Sriuranpong, Thailand
12.37 Unmet-medical need in NSCLC treatment
Speaker: Virote Sriuranpong, Thailand
12.45 Treatment strategies for EGFR- and ALK-driven NSCLC
Speaker: Caicun Zhou, China
13.10 Comprehensive genomic profiling: focus on lung cancer
Speaker: James Suh
13.25 Question and answer session
13.35 Final remarks and closing
Speaker: Virote Sriuranpong, Thailand

 

Sunday, 15 May 2016
11.25-12.25 Symposium supported by Novartis
Overcoming resistance in ALK-rearranged NSCLC patients
Room:
Empress Grand Hall, 3rd floor
11.25 Welcome and opening remark
Chairman: Tony  Mok, Hong Kong
11.30 Unmet medical need for second generation ALK inhibitors after patients fail crizotinib due to

  • Resistance
  • Brain metastases

How to individualise second generation ALK inhibitors to improve treatment outcomes?

  • Sequential rationale
  • Appropriate selection of those patients who may receive better benefit from second generation ALK inhibitors

Speaker: Tony  Mok, Hong Kong

12.00 Case sharing and discussion
Speaker:  Virote Sriuranpong, Thailand
12.20 Question and answer
Speakers: Tony  Mok, Hong Kong | Virote Sriuranpong, Thailand
12.35-13.35 Symposium supported by Merck:
Checkpoint Inhibition:  New Therapeutic Goals in Advanced NSCLC
Room:
Empress Grand Hall, 3rd floor
12.35 Welcome and Opening Remarks
Chairman: Sumitra Thongprasert, Thailand
12.40 Anti-PD-1 Experience in NSCLC
Updates on KN-001 and KN-010
Speaker: Myung-Ju Ahn, Korea
13.00 PD-L1 Expression in NSCLC
Speaker: Rina Hui, Australia
13.15 NSCLC Landscape: Where do we go from here?
Speaker: Tony Mok , Hong Kong
13.30 Closing Remarks
Chairman: Sumitra Thongprasert Thailand